Skip to content

Network to Understand Reproductive Rheumatology Registry

Network to Understand Reproductive Rheumatology Registry

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06940869
Acronym
NURTURE
Enrollment
1000
Registered
2025-04-23
Start date
2025-05-19
Completion date
2035-01-01
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases, Pregnancy Interest, Pregnancy Related, Reproductive Health, Rheumatic Diseases

Brief summary

The purpose of the NURTURE Registry is to enroll those who are pregnant and/or potentially capable of pregnancy. Participants will complete patient-reported surveys at enrollment and periodically prior to conception, during pregnancy, and following the completion of the study pregnancy. The study rheumatologist will provide the patient's diagnosis and record rheumatic disease activity at each clinic visit. Medication use, vital signs, and routine laboratory assessments will be collected throughout this period. Pregnancy, maternal, and infant outcomes will be obtained through the electronic medical record and from patient-reported surveys. This Registry will provide a rich data repository for research to improve pregnancy and birth outcomes for women with rheumatic diseases and will be used in on-going and future research to better understand the risk factors that are associated with poor pregnancy outcomes, including preterm birth, intrauterine growth restriction, and preeclampsia, as well as the effects of medication on disease management in pregnancy. Infant outcomes, medications, provider care, pregnancy planning, and social determinants of health on pregnancy and pregnancy outcomes will also be collected. The majority of the information collected in NURTURE, such as labs, disease activity, and medications, PRO's will originate from the EHR. Upon consent, participants will complete an enrollment survey that will include relevant patient reported measures. No study visits outside of routine care will occur. Participants may also complete a yearly survey about their reproductive health journey. The registry will be ongoing and will include periodic analysis of clinical data within this protocol. Additional analysis will be covered under seperate IRB approved protocols. Enrollment in the registry does not significantly increase the risk for a patient.

Detailed description

The purpose of the NURTURE Registry is to obtain information on those who are pregnant and/or potentially capable of pregnancy. This Registry will provide a rich data repository for research to improve pregnancy and birth outcomes for women with rheumatic diseases and will be used in on-going and future research to better understand the risk factors that are associated with poor pregnancy outcomes, including preterm birth, intrauterine growth restriction, and preeclampsia, as well as the effects of medication on disease management in pregnancy. Infant outcomes, medications, provider care, pregnancy planning, and social determinants of health on pregnancy and pregnancy outcomes will also be collected. Participation in NURTURE will be seamless with routine patient care. Any patient with a rheumatic disease seen by a participating site study provider as part routine care, and who could potentially become pregnant (females between the ages of 12 and 55), or who is currently pregnant, will be invited to participate in NURTURE. Participants will complete patient-reported surveys at enrollment and periodically prior to conception, during pregnancy, and following the completion of the study pregnancy. The study rheumatologist will provide the patient's diagnosis and record rheumatic disease activity at each clinic visit. Medication use, vital signs, and laboratory assessments will be collected as part of standard clinical care vistis and used in this registry. Pregnancy, maternal, and infant outcomes will be obtained through the electronic medical record and from patient-reported surveys. Prior to or at each standard of care (non-study, routine) visit, the patient will complete routine clinical questionnaires. This is a natural-history study and will not include medications, laboratory testing, or procedures outside of the standard of care. Management of the rheumatologic disease will be directed based on patient needs by the local rheumatologist and obstetrician. Enrollment in the registry will not dictate specific therapy.

Interventions

OTHERNURTURE Registry

To improve pregnancy and birth outcomes for women with rheumatic diseases and to understand risk factors associated with poor pregnancy outcomes.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of an automimmune or rheumatic condition determined by health care provider. 2. Age 12-55 who are capable of pregnancy (currently pregnant or planning a pregnancy). 3. A patient who receives their care in the Duke Health System. 4. Capable of providing informed consent.

Exclusion criteria

1\. Unable to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Edinburgh post-partum depression scaleup to 20 yearsDepression at entry in NURTURE defined by the Edinburgh Postnatal Depression Scale (EPDS) score ≥10 indicating minor depression.

Secondary

MeasureTime frameDescription
Readiness for Pregnancyup to 20 yearsWe will explore the effect size of the HOP-STEP Intervention on 'personally-ready and 'medically-ready' pregnancies by comparing women who did and did not receive the HOP-STEP Intervention. "Medically ready" will be defined as \<1g of proteinuria, no rheumatic teratogens at conception, and continuing pregnancy compatible SLE medications after conception. "Personally ready" will be defined as a planned pregnancy based on a London Measure of Unplanned Pregnancy (LMUP) score ≥10.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMegan Clowse

Professor of Medicine, Duke University Health System

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026